Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats

Journal of Pharmacy and Pharmacology

Volumn 51, Issue 11, 1999, Pages 1275-1282

  Behnia, Kamelia ^a,b   Boroujerdi, Mehdi ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRIAMYCINONE; ALDEHYDE REDUCTASE; CREATINE KINASE; DOXORUBICIN; DOXORUBICINOL; OXIDOREDUCTASE; PHENOBARBITAL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CYTOSOL; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; HEART; LIVER; LIVER CYTOSOL; MALE; NONHUMAN; RAT;

EID: 0033405349     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357991777010     Document Type: Article

References (26)

1. Ahmed, N. K., Felsted, R., Bachur, N. R. (1978) Heterogeneity of anthracycline antibiotic carbonyl reductases in mammalian livers. Biochem. Pharmacol. 27: 2713-2719
2. Behnia, K., Boroujerdi, M. (1998) Investigation of the enterohepatic recirculation of adriamycin and its metabolites by a linked-rat model. Cancer Chemother. Pharmacol. 41: 370-376
3. Bosron, W., Prairie, R. (1972) Triphosphopyridine nucleotide-linked aldehyde reductase. J. Biol. Chem. 274: 4480-4485
4. Boyd, M. R., Burka, L. T., Benjamen, J. W., Sasame, H. A. (1978) In vitro studies on the metabolic activation of the pulmonary toxin, 4-ipomeanol by rat lung and liver microsomes 207: 677-686
5. Bronaugh, R. L., Erwin, G. (1973) Partial purification and characterisation of NADPH-linked aldehyde reductase from monkey brain. J. Neurochem. 21: 809-815
6. Buzdar, A. U., Marcus, C., Terryl-Smith, R. N., Blumenshein, G. R. (1985) Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 55: 2761-2765
7. Danesi, R., Del Tacca, M. D., Della Torre, P., Bernardini, C. (1986) General and cardiac toxicity of adriamycinol in rat. Anticancer Res. 6: 967-972
8. Del Tacca, M., Danesi, R., Ducci, M., Bernardini, C., Romanini, A. (1985) Might adriamycinol contribute to adriamycin-induced cardiotoxicity? Pharmacol. Res. Commun. 17: 1073-1084
9. Doroshow, J. H., Locker, G. Y., Ifrim, I., Myers, C. E. (1981) Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J. Clin. Invest. 68: 1053-1064
10. Erwin, V. G., Heston, W. D. W., Tabakoff, B. (1972) Purification and characterisation of an NADH-linked aldehyde reductase from bovine brain. J. Neurochem. 19: 2269-2278
11. Felsted, R. L., Richter, D., Bachur, R. N. (1977) Rat liver aldehyde reductase. Biochem. Pharmacol. 26: 1117-1124
12. Funae, Y., Imaoka, S. (1993) Cytochrome P450 in rodents. In: Schenkman, J. B., Greim, H. (eds) Cytochrome P450, Handbook of Experimental Pharmacology. Vol. 105. Springer-Verlag, pp 221-238
13. Gewirtz, D. A., Yanovich, S. (1987) Metabolism of adriamycin in hepatocytes isolated from the rat and the rabbit. Biochem. Pharmacol. 36: 1793-1798
14. Inazu, N., Hayashi, M., Hiura, M., Satoh, T. (1996) Effect of psychotropic drugs on aldo-keto reductase activity in rat ovary and adrenal gland. Biochem. Pharmacol. 52: 1581-1591
15. Kawalek, J. C., Gilbertson, J. R. (1976) Partial purification of the NADPH-dependent aldehyde reductase from bovine cardiac muscle. Arch. Biochem. Biophys. 173: 649-657
16. Lee, B. H., Goodenday, L., Muswick, G. (1987) Alterations in left ventricular diastolic function with doxorubicin therapy. J. Am. Coll. Cardiol. 9: 184-188
17. Lefrak, E. A., Pitha, J., Rosenheim, S., Gottlieb, J. (1973) Clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32: 302-314
18. Ludden, T. M., Beal, S. L., Sheiner, L. B. (1994) Comparison of the Akaike information criterion, the Schwarz criterion and the F-Test as guide to model selection. J. Pharmacokin. Biopharm. 22: 431-445
19. Minotti, G., Cavaliere, A. F., Moredente, A., Rossi, M., Schiavello, R., Zamparelli, R., Possati, G. (1995) Secondary alcohol metabolites mediate iron de-localisation in cystolic fraction of myocardial biopsies exposed to anticancer anthracyclines. Novel link between anthracycline metabolism and iron-induced cardiotoxicity. J. Clin. Invest. 95: 1595-1605
20. Myers, C. E. (1992) Anthracyclines. In: Pinedo, H. M., Longo, D. L., Chabner, B. A. (eds) Cancer Chemotherapy and Biological Modifiers Annual 13. Elsevier, New York, p. 45
21. Mylari, B. L., Beyer, T. A., Siegel, T. W. (1991) A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners. 34: 1011-1018
22. Olson, R. D., Mushlin, P. S., Brenner, D. E., Fleischer, S., Chang, B. K., Cusack, B. J., Boucek, R. J. (1988) Doxorubicin cardiotoxicity may be caused by its metabolite doxorubicinol. Proc. Natl Acad. Sci. 85: 3585-3589
23. Powis, G. (1991) Toxicity of free radical forming anticancer drugs. In: Powis, G., Hacker, M. P. (eds) The Toxicity of Anticancer Drugs. Pergamon, New York, pp 106-132
24. Tulsiani, D. R. P., Touster, O. (1977) Resolution and partial characterisation of two aldehyde reductases of mammalian liver. J. Biol. Chem. 252: 2545-2550
25. Vora, J., Boroujerdi, M. (1996) Pharmacokinetic-toxicodynamic relationships of adriamycin in rat: prediction of butylated hydroxyanisole-mediated reduction in anthracyclin cardiotoxicity. J. Pharm. Pharmacol. 48: 1264-1269
26. Waxman, D. J. (1992) Phenobarbital induction of cytochrome P-450 gene expression. Biochem. J. 281: 577-592